Skip to main content
SpringerLink
Log in

Metabolic effects of dopamine-agonists treatment among patients with prolactinomas

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effect of cabergoline treatment on metabolic parameters including the Triglyceride-glucose (TyG) index in newly diagnosed patients with prolactinoma.

Methods

71 consecutive nondiabetic patients with prolactinoma were enrolled. Anthropometric and laboratory tests including TyG index were measured at baseline, 3 and 6 months visits. Treatment with cabergoline at the dose of 0.25 mg twice weekly was started and increased according to prolactin levels and continued for 6 months.

Results

At the baseline examination, the mean (SD) age, body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) of patients were 36.2 (10.5) years, 29.2 (5.0) kg/m2, 98.2 (13.7) cm, 115.3 (13.3) mmHg, and 71.4 (8.1) mmHg, respectively. Forty-one (57.7%) of patients were women and 46 (64.8%) had microadenoma. Cabergoline treatment significantly improved anthropometric and metabolic measures including BMI, WC, fasting plasma glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid (only among women), TyG index, and hypogonadism. Blood pressure (both systolic and diastolic) levels remained steady except for a significant decrease in DBP after 6 months of treatment only among women. A declining trend in MetS prevalence was found from baseline to a 3-month evaluation in both genders which was statistically significant among men.

Conclusion

Short-term treatment with cabergoline can significantly improve cardiovascular risk factors except for blood pressure. Moreover, the TyG index as a surrogate marker of insulin resistance decreased significantly after the reduction of prolactin by treatment. Generally, results were similar among both genders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

All data and materials are available upon request.

References

  1. M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao. Advances in the treatment of prolactinomas. 27(5), 485–534 (2006)

  2. B.A. Doğan, A. Arduç, M.M. Tuna, N.I. Nasıroğlu, S. Işık, D. Berker et al. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatol. J. Cardiol. 16(6), 440 (2016)

    PubMed  Google Scholar 

  3. R. Haring, N. Friedrich, H. Völzke, R.S. Vasan, S.B. Felix, M. Dörr et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 35(18), 1215–1221 (2014)

    Article  CAS  PubMed  Google Scholar 

  4. A. Jurek, P. Krzesiński, G. Gielerak, B. Uziębło-Życzkowska, P. Witek, G. Zieliński et al. Prolactinoma and cardiovascular diseases–an interdisciplinary problem. Pediatr. Med Rodz. 2021 17(4), 294–298 (2021). https://doi.org/10.15557/PiMR.2021.0046

    Article  Google Scholar 

  5. O. Serri, L. Li, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. 64(4), 366–370 (2006)

    CAS  Google Scholar 

  6. C.M. Silva, F.R. Barbosa, G.A. Lima, L. Warszawski, R. Fontes, R.C. Domingues et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obes. (Silver Spring) 19(4), 800–805 (2011)

    Article  Google Scholar 

  7. J. Krogh, C. Selmer, C. Torp-Pedersen, G.H. Gislason, C. Kistorp, Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm. Metab. Res. 49(06), 411–417 (2017)

    Article  CAS  PubMed  Google Scholar 

  8. K.E. Therkelsen, T.M. Abraham, A. Pedley, J.M. Massaro, P. Sutherland, U. Hoffmann et al. Association between prolactin and incidence of cardiovascular risk factors in the Framingham Heart Study. J. Am. Heart Assoc. 5(2), e002640 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  9. S.S. Inancli, A. Usluogullari, Y. Ustu, S. Caner, A.A. Tam, R. Ersoy et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1), 193–199 (2013)

    Article  CAS  PubMed  Google Scholar 

  10. D. Yavuz, O. Deyneli, I. Akpinar, E. Yildiz, H. Gozu, O. Sezgin et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol. 149(3), 187–194 (2003)

    Article  CAS  PubMed  Google Scholar 

  11. S. Byberg, J. Futtrup, M. Andreassen, J. Krogh, Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr. Connect. 8(10), 1395–1404 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120(16), 1640–1645 (2009)

    Article  CAS  PubMed  Google Scholar 

  13. F. Azizi, D. Khalili, H. Aghajani, A. Esteghamati, F. Hosseinpanah, A. Delavari et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Archives of Iranian Medicine. 13(3) (2010)

  14. S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011)

    Article  CAS  PubMed  Google Scholar 

  15. N.A. Pala, B.A. Laway, R.A. Misgar, R.A. Dar, Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol. Metab. Syndr. 7(1), 1–6 (2015)

    Article  Google Scholar 

  16. N.A. Pala, B.A. Laway, R.A. Misgar, Z.A. Shah, T.A. Gojwari, T.A. Dar, Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. Indian J. Endocrinol. Metab. 20(2), 177 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. R.S. Auriemma, D. De Alcubierre, R. Pirchio, R. Pivonello, A. Colao, The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev. Endocrinol. Metab. 13(2), 99–106 (2018)

    Article  CAS  PubMed  Google Scholar 

  18. R.S. Auriemma, M. Galdiero, P. Vitale, L. Granieri, F.L. Calzo, C. Salzano et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101(1), 66–81 (2015)

    Article  CAS  PubMed  Google Scholar 

  19. K. Berinder, T. Nyström, C. Höybye, K. Hall, A.-L. Hulting, Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3), 199–207 (2011)

    Article  CAS  PubMed  Google Scholar 

  20. A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. 79(6), 84–852 (2013)

    Article  Google Scholar 

  21. V. Schwetz, R. Librizzi, C. Trummer, G. Theiler, C. Stiegler, T.R. Pieber et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab. Brain Dis. 32(1), 155–161 (2017)

    Article  CAS  PubMed  Google Scholar 

  22. R.S. Auriemma, L. Granieri, M. Galdiero, C. Simeoli, Y. Perone, P. Vitale et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98(4), 299–310 (2013)

    Article  CAS  PubMed  Google Scholar 

  23. A.S. Posawetz, C. Trummer, M. Pandis, F. Aberer, T.R. Pieber, B. Obermayer-Pietsch et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr. Disord. 21(1), 1–9 (2021)

    Article  Google Scholar 

  24. I.B. Andersen, M. Andreassen, J. Krogh, The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: a systematic review with meta analysis and trial sequential analysis of randomized clinical trials. Diabetes, Obes. Metab. 23(1), 58–67 (2021)

    Article  CAS  PubMed  Google Scholar 

  25. E. Lamos, D. Levitt, K. Munir, A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Prim. Care Diabetes 10(1), 60–65 (2016)

    Article  CAS  PubMed  Google Scholar 

  26. S.M. Taghavi, S.S. Fatemi, H. Rokni, Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med. J. Malays. 67(4), 390–392 (2012)

    Google Scholar 

  27. A. Bahar, Z. Kashi, E. Daneshpour, O. Akha, S. Ala, Effects of cabergoline on blood glucose levels in type 2 diabetic patients: a double-blind controlled clinical trial. Medicine 95(40), e4818 (2016). https://doi.org/10.1097/MD.0000000000004818

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. A. Aliasgarzadeh, S. Karimiavval, J. Houshyar, M. Gojazadeh, A. Hadi, Evaluating the effect of cabergoline on glycaemic control of patients with type 2 diabetes mellitus: a randomised controlled trial. J. Clin. Diagnostic Res. 14(2), OC01–OC04 (2020)

    Google Scholar 

  29. A.C.J. Vasques, F.S. Novaes, M.D.S. de Oliveira, J.R.M. Souza, A. Yamanaka, J.C. Pareja et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res. Clin. Pract. 93(3), e98–e100 (2011)

    Article  CAS  PubMed  Google Scholar 

  30. K. Zhang, Y. Chen, L. Liu, M. Lu, J. Cheng, F. Gao et al. The Triglycerides and Glucose Index rather than HOMA-IR is more associated with Hypogonadism in Chinese men. Sci. Rep. 7(1), 1–7 (2017)

    Google Scholar 

  31. F. Guerrero-Romero, L.E. Simental-Mendía, M. González-Ortiz, E. Martínez-Abundis, M.G. Ramos-Zavala, S.O. Hernández-González et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab. 95(7), 3347–3351 (2010)

    Article  CAS  PubMed  Google Scholar 

  32. L.E. Simental-Mendía, M. Rodríguez-Morán, F. Guerrero-Romero, The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 6(4), 299–304 (2008)

    Article  PubMed  Google Scholar 

  33. L. Sánchez‐Íñigo, D. Navarro‐González, A. Fernández‐Montero, J. Pastrana‐Delgado, J.A. Martínez, The TyG index may predict the development of cardiovascular events. Eur. J. Clin. Invest. 46(2), 189–197 (2016)

    Article  PubMed  Google Scholar 

  34. S. Li, B. Guo, H. Chen, Z. Shi, Y. Li, Q. Tian et al. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci. Rep. 9(1), 1–9 (2019)

    Google Scholar 

  35. S.H. Khan, F. Sobia, N.K. Niazi, S.M. Manzoor, N. Fazal, F. Ahmad et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistace. Diabetol. Metab. Syndr. 10(1), 1–8 (2018)

    Article  Google Scholar 

  36. F. Azizi, F. Hadaegh, F. Hosseinpanah, P. Mirmiran, A. Amouzegar, H. Abdi et al. Metabolic health in the Middle East and North Africa. Lancet Diabetes Endocrinol. 7(11), 866–879 (2019)

    Article  PubMed  Google Scholar 

  37. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120(16), 1640–1645 (2009)

    Article  CAS  PubMed  Google Scholar 

Download references

Author contributions

M.K., H.A, and F.G. planned the study, researched the data, and wrote the manuscript. S.M. and A.K analyzed the data and edited the manuscript. H.S. reviewed and edited the manuscript.

Author information

Authors and Affiliations

  1. Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

    Maryam Kabootari

  2. Clinical Research Development Unit, Sayad Shirazi Hospital, Golestan University of Medical Science, Gorgan, Iran

    Habibeh Shirmohammadli & Hamideh Akbari

  3. Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

    Fatemeh Golgiri

  4. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    Seyedarad Mosalamiaghili

  5. Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Alireza Khajavi

Authors
  1. Maryam Kabootari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Habibeh Shirmohammadli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Golgiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyedarad Mosalamiaghili
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alireza Khajavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hamideh Akbari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hamideh Akbari.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical Approval

This study was approved by the Ethics Committee of the Golestan University of Medical Science (Protocol no. IR.GOUMS.REC.1398.300) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

Informed consent for publication was obtained from patients.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kabootari, M., Shirmohammadli, H., Golgiri, F. et al. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas. Endocrine 79, 537–544 (2023). https://doi.org/10.1007/s12020-022-03238-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-022-03238-x

Keywords

Search

Navigation